Research
Hormonal
Exogenous leptin administration fails to produce significant weight loss in individuals with common obesity due to central leptin resistance, despite being effective in treating congenital leptin deficiency.
Taking leptin supplements or relying on high-leptin foods will not help you lose weight if you have common obesity. Your body already produces high levels of leptin but has become resistant to its signals. Effective treatment requires addressing this resistance, not just adding more hormone.
GoodRefutesHIGH confidence
However, in individuals with obesity, serum leptin concentrations are increased and do not reduce food intake or improve hyperglycemia [34]. Moreover, exogenous administration of leptin does not significantly influence appetite and body weight in obese patients, a phenomenon which has been attributed to central leptin resistance [37].
Why this rating
Based on a comprehensive review of clinical trials and established biological mechanisms described in the text.
Source
Adipokines – removing road blocks to obesity and diabetes therapy
Matthias Blüher · Molecular Metabolism · 2014
DOI 10.1016/j.molmet.2014.01.005
narrative_reviewCited 269×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Adipokine-based therapies face major biological roadblocks including lack of efficacy in humans despite rodent success, incomplete understanding of mechanisms, and adverse side effects.Strong
- Combining leptin analogs (metreleptin) with amylin analogs (pramlintide) can restore leptin sensitivity and produce significant weight loss in obesity, overcoming the resistance seen with leptin monotherapy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →